Kamada (KMDA), Kedrion Submit BLA to FDA for Human Rabies Immunoglobulin as Post-Exposure Treatment
- Oil rallies over $50 despite OPEC output cut doubts
- lululemon athletica (LULU) Tops Q3 EPS by 4c; Adj.-Comps Outpaced Views
- Costco Wholesale (COST) Tops Q1 EPS by 5c; Comps Up 1%, 2% Ex-Gas
- Universal Health (UHS) Disputes and Denies Conclusions in BuzzFeed Article
- Perrigo (PRGO) to Restructure BCH Omega Pharma Belgium Business; Will Terminate EuroGenerics Agreement
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Kamada Ltd. (Nasdaq: KMDA) and Kedrion S.p.A., the parent company of Kedrion Biopharma Inc., a company focused on plasma-derived proteins used in treating and preventing serious diseases and disorders, announced the submission of a Biological License Application (BLA) has been filed with the U.S. Food and Drug Administration (FDA) for a post-exposure treatment for rabies, a life-threatening condition. The human anti-rabies immune globulin (IgG) therapy was developed as a collaboration between the two companies.
Kamada and Kedrion have a strategic agreement for the clinical development and marketing of the anticipated new IgG rabies treatment in the U.S. Kamada will hold the license for the approved product and Kedrion will exclusively market the therapy in the U.S., subject to receiving marketing approval from the FDA.
Kamada has been selling the product since 2003 in numerous territories outside the U.S. under the brand name KamRAB™. Kamada has sold more than one million vials of the product to date, demonstrating significant clinical and safety experience with the product.
“We are pleased to achieve this important milestone in the development of our human rabies immunoglobulin,” said Amir London, Chief Executive Officer of Kamada. “In the U.S., approximately 40,000 post-exposure prophylaxis treatments are administrated each year, representing an annual market opportunity of over $100 million. We believe we have a safe and effective product that, if approved, has the potential to gain meaningful market share over time.”
“Kedrion is pleased to be collaborating on the clinical development and anticipated commercialization of an important new rabies treatment here in the United States,” said Paolo Marcucci, President and Chief Executive Officer of Kedrion S.p.A. “We have recognized that a clear need exists for an additional rabies treatment option. Kedrion will be making a significant contribution to the health and welfare of large numbers of people who may have been exposed to a life-threatening but completely treatable condition.”
The BLA is based on results announced in December 2015 from a prospective, randomized, double-blind, non-inferiority Phase 2/3 study of 118 healthy subjects. The study evaluated pharmacokinetic (PK) parameters of anti-rabies IgG levels in serum at different time points and assessed whether the human rabies IgG interferes with the development of endogenous antibodies. Study results showed that the primary endpoint of non-inferiority was met with a difference of -1.8 percent between the two therapies with variability between -8.2 percent and 3.1 percent (90 percent confidence limit). No drug-related Serious Adverse Events (SAEs) were experienced by study subjects.
Kamada and Kedrion expect a regulatory decision from the FDA on the BLA in mid-2017, and plan on launching the product soon after a favorable decision.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BioDelivery Sciences (BDSI) Announces Reacquisition of BELBUCA Rights from Endo (ENDP)
- GTx, Inc. (GTXI) Announces Early Initial Success from Ongoing Enobosarm Phase 2 in ER+/AR+ Breast Cancer
- USANA Health Sciences (USNA) Names New CIO and President
Create E-mail Alert Related CategoriesCorporate News, FDA, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!